Jacobio Pharmaceuticals Group Co., Ltd. released its earnings results on Aug 29, 2025. The company reported -HK$0.09 earnings per share for the quarter, beating the consensus estimate of -HK$0.191 by HK$0.101.

Is Jacobio Pharmaceuticals Group Co., Ltd. overvalued?

According to Wall Street analysts Jacobio Pharmaceuticals Group Co., Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Jacobio Pharmaceuticals Group Co., Ltd. pay dividends?

Jacobio Pharmaceuticals Group Co., Ltd. does not currently pay dividends.

What is Jacobio Pharmaceuticals Group Co., Ltd.’s EPS estimate?

Jacobio Pharmaceuticals Group Co., Ltd.’s EPS estimate is 0.03.

How many shares outstanding does Jacobio Pharmaceuticals Group Co., Ltd. have?

Jacobio Pharmaceuticals Group Co., Ltd. has 791,755,070 shares outstanding.

What happened to Jacobio Pharmaceuticals Group Co., Ltd.’s price movement after its last earnings report?

Jacobio Pharmaceuticals Group Co., Ltd. reported an EPS of -HK$0.09 in its last earnings report, beating expectations of -HK$0.191. Following the earnings report the stock price went up 9.299%.

Which hedge fund is a major shareholder of Jacobio Pharmaceuticals Group Co., Ltd.?

Currently, no hedge funds are holding shares in HK:1167

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Jacobio Pharmaceuticals Group Co., Ltd. Stock Smart Score

Outperform

Technicals

Fundamentals

Return on Equity

-5.08%

Trailing 12-Months

Asset Growth

0.29%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Jacobio Pharmaceuticals Group Co., Ltd.

Jacobio Pharmaceuticals Co., Ltd., a clinical-stage pharmaceutical company, focusing on the in-house discovery and development of oncology therapies. The company's lead drug development programs include two clinical-stage allosteric Src homology region 2 domain-containing phosphatase-2 (SHP2) inhibitors comprising JAB-3312 and JAB-3068 for the treatment of esophageal cancer; JAB-8263, a small molecule inhibitor of BET family proteins regulating MYC transcription to treat various cancers; and JAB-21822, an oral small molecule targeting mutant KRAS G12C protein. It is also develops JAB-BX102, a humanized inhibitory antibody against human CD73 for the treatment of PD-1 resistant cancer; JAB-6343, an inhibitor that targets fibroblast growth factor receptor 4 for advanced hepatocellular carcinoma with FGF19 overexpression; JAB-2485, an aurora A kinase inhibitor for solid tumors; JAB-24114, a tumor metabolic pathway for the treatment of solid tumors; and JAB-BX300, a molecule antibody targeting RAS pathway to treat pancreatic and other solid tumors with KRAS mutations. The company has a strategic collaboration with AbbVie Ireland Unlimited Company to develop and commercialize SHP2 inhibitors. Jacobio Pharmaceuticals Co., Ltd. was incorporated in 2015 and is headquartered in Beijing, China.